Search academic texts

Information × Registration Number 0225U003077, (0122U000119) , R & D reports Title Development of a strategy for the diagnosis, treatment and prediction of chronic heart failure of ischemic origin on the background of metabolic disorders popup.stage_title Розробка стратегії діагностики, лікування та прогнозування перебігу хронічної серцевої недостатності ішемічного ґенезу на тлі метаболічних порушень Head Kravchun Pavlo Н., д.мед.н. Registration Date 14-05-2025 Organization Kharkiv National Medical University popup.description1 Іmproving the effectiveness of diagnosis and treatment of chronic heart failure in patients with coronary heart disease on the background of concomitant obesity and type 2 diabetes mellitus based on the determination of humoral parameters: galectin-3, nesfatin-1, Gas6 protein, cathestatin, NTproBNP, parameters , assessment of their prognostic value in the course of chronic heart failure of ischemic origin in the presence of metabolic disorders popup.description2  The following were established: the activity of galectin-3, nesfatin-1, catestatin and NTproBNP in blood plasma in accordance with changes in lipid and carbohydrate profile parameters, changes in psycho-emotional state and quality of life of patients with chronic heart failure of ischemic genesis depending on the presence of concomitant metabolic disorders. The presence and nature of relationships between cardiohemodynamic indicators, markers of adipogenesis, systemic immune inflammation, fibrogenesis, cardiovascular remodeling and metabolic disorders depending on the functional class of heart failure in patients with ischemic heart disease on the background of concomitant type 2 diabetes mellitus and obesity were proven; the effect of standard combined treatment of patients with coronary heart disease and chronic heart failure on increasing exercise tolerance, improving quality of life, a significant decrease in proatherogenic lipid fractions, a decrease in insulin resistance, a significant decrease in the concentration of the fibrosis marker galectin-3, a decrease in NT-pro-BNP content by 52.5%, and an improvement in the clinical condition of patients. Product Description popup.authors Babadzhan Volodymyr D. Borovyk Kateryna M. Kadykova Olha Ih. Kravchun Pavlo H. Ryndina Nataliia H. popup.nrat_date 2025-05-14 Close